title: The basis for HIV immunotherapeutic vaccines.
abstract: The drug treatments introduced in recent years for HIV infection have enabled a marked reduction in morbidity and prolongation of life. These treatments, however, are often associated with acute and chronic toxicities, the development of resistant virus can limit their effectiveness, and they are too expensive and difficult to administer in most third world settings. A successful HIV immunotherapeutic vaccine has the potential to overcome these problems, and would be a valuable advance. The most promising approaches have induced the type of immune response found to correlate with reduced activity of HIV in man, especially cytotoxic T-cell responses, or have led to reduced HIV or SIV viral load and increased CD4 counts in non-human primates or man. The agents that have led to one or both of these effects have been selected for review, and include inactivated envelope depleted virus, recombinant envelope glycoprotein, DNA vaccines utilising HIV peptides or gene products, viral vectors, such as canarypox or attenuated vaccinia, with HIV core proteins. There are other approaches, such as alloimmunity, for which no candidate products yet exist, but which conceptually appear promising. Currently, however, only a few phase III studies of HIV therapeutic vaccines have been completed in man, and there has been a modest therapeutic effect. Further development of both existing and new candidates remains one of the key priorities in our fight against HIV.
authors.affiliation: Department of GU Medicine, GKT School of Medicine, Harrison Wing, St. Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, UK. barry.peters@gstt.sthames.nhs.uk
authors.forename: B S
authors.initials: BS
authors.lastname: Peters
mesh_terms: D016915:AIDS Vaccines / Q000627:therapeutic use*; D015696:Gene Products, tat / Q000276:immunology; D005822:Genetic Vectors; D006678:HIV / Q000276:immunology; D016655:HIV Core Protein p24 / Q000627:therapeutic use; D015658:HIV Infections / Q000276:immunology* / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007519:Isoantigens / Q000008:administration & dosage; D019444:Vaccines, DNA / Q000627:therapeutic use; D014759:Viral Envelope Proteins / Q000276:immunology; D014765:Viral Vaccines / Q000627:therapeutic use; D054322:tat Gene Products, Human Immunodeficiency Virus
chemical_list: D016915:AIDS Vaccines; D015696:Gene Products, tat; D016655:HIV Core Protein p24; D007519:Isoantigens; C078787:NYVAC vaccine; D019444:Vaccines, DNA; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; C065031:p24-VLP vaccine; C105086:remune; D054322:tat Gene Products, Human Immunodeficiency Virus